Wites & Kapitan

Call For Free Consultation

INVESTOR ALERT: WITES & KAPETAN ANNOUNCES INVESTIGATION OF NQ MOBILE, INC.’S DECLINE IN SHARE VALUE AND POSSIBLE CLASS ACTION LAWSUIT

Wites & Kapetan, P.A. is announcing their investigation of NQ Mobile, Inc. (“NQ Mobile” or the “Company”) (NYSE: NQ). On October 24, 2013, Muddy Waters Research announced a “strong sell” rating on NQ Mobile stock, calling the Chinese developer of mobile security software a “massive fraud.”  The Muddy Waters report asserts that NQ Mobile has greatly exaggerated its true financial performance and its market share in China.    On October 24, 2013 following this news, NQ Mobile’s stock price declined by $10.79 per share, more than 47%, to close at $12.09 per share.  On October 25, 2013, NQ Mobile responded to the Muddy Waters...

Read More

INVESTOR ALERT: WITES & KAPETAN, P.A. ANNOUNCES EXTENSION OF TIME PERIOD FOR INVESTOR LOSSES IN J.C. PENNY STOCK

Wites & Kapetan, P.A. announces that the time period for losses in J.C. Penny Company Inc. stock (NYSE: JCP) has been extended, and now includes May 16, 2013 through and including September 26, 2013. If you are an investor who purchased J.C. Penny Common Stock between May 16, 2013 and September 26, 2013, you may have a legal claim against JC Penny and could serve as the lead plaintiff in the case. The deadline for filing for lead plaintiff is December 2, 2013. If you are interested in being the lead plaintiff, or would like to speak with an attorney about...

Read More

INVESTOR ALERT: INVESTIGATION OF BIOSCRIP, INC. AND POSSIBLE CLASS ACTION LAWSUIT

Wites & Kapetan, P.A. is announcing their investigation of BioScrip, Inc. (“BioScrip” or the “Company”)(Nasdaq: BIOS) and a possible class action lawsuit which may allege that the Company and certain of its officers and directors committed violations of the Securities Exchange Act of 1934.  On September 23, 2013, BioScrip disclosed in a Securities and Exchange Commission (SEC) Form 8-K filing that the Company received a civil investigative demand issued by the United States Attorney’s Office for the Southern District of New York and a subpoena from the New York State Attorney General’s Medicaid Fraud Control Unit regarding the distribution of the Novartis Pharmaceuticals Corporation product...

Read More

Wites & Kapetan, P.A. Investigates Filing Class Action Lawsuit Against Urban Outfitters

Wites & Kapetan, P.A. is announcing their investigation of Urban Outfitters, Inc. (Nasdaq: URBN) and a possible class action lawsuit which may allege that the company and certain of its officers and directors committed violations of the Securities Exchange Act of 1934. On September 9, 2013 after the market closed, Urban Outfitters, Inc. (“Urban Outfitters” or the “Company”) disclosed its second quarter 2013 financial results and commented on third quarter 2014 expectations in a quarterly financial report filed on Form 10-Q with the SEC.  Comparable sales at the Company’s Urban Outfitters Group had grown only 5.2% in the 2014 second quarter, far less than the...

Read More

WITES & KAPETAN, P.A. ANNOUNCES THAT CLASS ACTION LAWSUITS HAVE BEEN FILED AGAINST ARIAD PHARMACEUTICALS

Wites & Kapetan, P.A. announces that class action lawsuits have been filed against ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) which allege that the Company and certain of its officers and directors committed violations of the Securities Exchange Act of 1934. The complaints allege that on October 9, 2013, ARIAD reported that 11.8% of Iclusig-treated patients experienced serious arterial thrombosis.  As a result, the Company said it was halting all enrollment in Iclusig clinical trials and that the Food and Drug Administration (FDA) had also placed a partial hold on the trials due to the serious arterial thrombosis occurring in Iclusig-treated patients. On...

Read More

WITES & KAPETAN, P.A. ANNOUNCES THAT CLASS ACTION LAWSUITS HAVE BEEN FILED AGAINST J.C. PENNY COMPANY

Wites & Kapetan, P.A. announces that class action lawsuits have been filed that allege that JC Penny Company, Inc. (NYSE: JCP) and certain of its officers and directors committed violations of the Securities Exchange Act of 1934. The complaints allege that the company made materially false and misleading statements to the investing public about the company’s financial health, including that the company would not have sufficient money to operate through the end of the year, that it would require additional investments to get through the holiday season, and that it hid such information so as not to worry its vendors.  It...

Read More